Polatuzumab (CAS 2279068-37-8) is a monoclonal antibody that targets CD79b, a protein found on malignant B cells. It is used to create polatuzumab vedotin, an antibody-drug conjugate (ADC) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab.
Key Features:
- Target Specificity: Binds to CD79b on B cells.
- Mechanism of Action: Delivers a cytotoxic agent to B cells, causing cell death.
- Molecular Characteristics: Monoclonal antibody conjugated with a cytotoxic agent.
Applications:
- Antibody-Drug Conjugates (ADCs): Used for targeted therapy.
- Cancer Therapy: Effective in treating relapsed or refractory DLBCL.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
